[go: up one dir, main page]

SI2678351T1 - Hiv-gp-120-varianta - Google Patents

Hiv-gp-120-varianta Download PDF

Info

Publication number
SI2678351T1
SI2678351T1 SI201231116T SI201231116T SI2678351T1 SI 2678351 T1 SI2678351 T1 SI 2678351T1 SI 201231116 T SI201231116 T SI 201231116T SI 201231116 T SI201231116 T SI 201231116T SI 2678351 T1 SI2678351 T1 SI 2678351T1
Authority
SI
Slovenia
Prior art keywords
polypeptide
hiv
polynucleotide
sample
expression vector
Prior art date
Application number
SI201231116T
Other languages
English (en)
Inventor
Herranz Maria Eloisa Yuste
Merino Victor Sanchez
Carolina Ferreira
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Fundacio Privada Institut De Recerca De La Sida-Caixa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve, S.A., Fundacio Privada Institut De Recerca De La Sida-Caixa filed Critical Laboratorios Del Dr. Esteve, S.A.
Publication of SI2678351T1 publication Critical patent/SI2678351T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)

Claims (13)

  1. Imenovanje Slovenije pri EP 2 678 351 BI HIV-GP-120-VARIANTA Patentni zahtevki
    1. Polipeptid, ki je zmožen izzvati nevtralizacijska protitelesa proti virusu, ki obsega varianto HIV-1 gpl20 ali imunogen delec le-tega, pri čemer polipeptid ali imunogen delec le-tega obsega zaporedje ZAP ID ŠT: 4.
  2. 2. Protitelo, ki se veže specifično na polipeptid po zahtevku 1.
  3. 3. Polinukleotidno kodiranje polipeptida po zahtevku 1.
  4. 4. Polinukleotid po zahtevku 3, ki ima zaporedje ZAP ID ŠT: 3.
  5. 5. Izrazni vektor, ki obsega polinukleotid po zahtevku 4.
  6. 6. Gostiteljska celica, ki obsega polipeptid po zahtevku 1, polinukleotid po zahtevku 3 ali izrazni vektor po zahtevku 5.
  7. 7. Imunogena sestava ali cepivo, ki obsega polipeptid po zahtevku 1, polinukleotid po zahtevku 3 ali izrazni vektor po zahtevku 5.
  8. 8. Polipeptid po zahtevku 1, polinukleotid po zahtevku 3, izrazni vektor po zahtevku 5 ali imunogena sestava ali cepivo po zahtevku 7 za uporabo v medicini.
  9. 9. Polipeptid po zahtevku 1, polinukleotid po zahtevku 3, izrazni vektor po zahtevku 5 ali imunogena sestava ali cepivo po zahtevku 7 za uporabo pri preprečevanju bolezni, ki jo — w m « povzroči HIV infekcija.
  10. 10. Postopek za zaznavanje v vzorcu nevtralizacijskih protiteles, ki so specifična proti danemu patogenu, ki obsega: (i) postavitev omenjenega vzorca v stik s polipeptidom po zahtevku 1 in (ii) zaznavanje tvorbo imunskega kompleksa med omenjenim polipeptidom in omenjenimi nevtralizacijskimi protitelesi.
  11. 11. In vitro postopek za zaznavanje odziva nevtralizacijskega protitelesa proti virusni infekciji pri subjektu, ki obsega zaznavanje prisotnosti nevtralizacijskih teles v vzorcu omenjenega subjekta z uporabo postopka po zahtevku 10, pri čemer je prisotnost nevtralizacijskih protiteles v omenjenem vzorcu, glede na kontrolni subjekt, indikativna za odziv nevtralizacijskega protitelesa na virusno infekcijo v omenjenem subjektu.
  12. 12. Postopek po zahtevku 10 ali 11, pri čemer je virus HIV.
  13. 13. Postopek, kot je definiran v zahtevku 12, pri čemer je vzorec iz pacienta, ki je okužen s HIV-1, ali pri čemer je vzorec iz prejemnika AIDS cepiva.
SI201231116T 2011-02-25 2012-02-24 Hiv-gp-120-varianta SI2678351T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446595P 2011-02-25 2011-02-25
EP11382051A EP2492279A1 (en) 2011-02-25 2011-02-25 Rapid immunogen selection method using lentiviral display
EP12705689.3A EP2678351B1 (en) 2011-02-25 2012-02-24 Hiv gp-120 variant
PCT/EP2012/053185 WO2012113921A1 (en) 2011-02-25 2012-02-24 Rapid selection method for hiv gp-120 variants

Publications (1)

Publication Number Publication Date
SI2678351T1 true SI2678351T1 (sl) 2018-01-31

Family

ID=44246584

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231116T SI2678351T1 (sl) 2011-02-25 2012-02-24 Hiv-gp-120-varianta

Country Status (23)

Country Link
US (1) US9605030B2 (sl)
EP (2) EP2492279A1 (sl)
JP (1) JP6140614B2 (sl)
KR (1) KR20140025356A (sl)
CN (1) CN103459410B (sl)
AU (1) AU2012219418C1 (sl)
CA (1) CA2827967A1 (sl)
CY (1) CY1119638T1 (sl)
DK (1) DK2678351T3 (sl)
ES (1) ES2651124T3 (sl)
HR (1) HRP20171697T1 (sl)
HU (1) HUE035432T2 (sl)
IL (1) IL228094A0 (sl)
LT (1) LT2678351T (sl)
ME (1) ME03045B (sl)
MX (1) MX348459B (sl)
PL (1) PL2678351T3 (sl)
PT (1) PT2678351T (sl)
RS (1) RS56707B1 (sl)
RU (1) RU2603732C2 (sl)
SI (1) SI2678351T1 (sl)
SM (1) SMT201700571T1 (sl)
WO (1) WO2012113921A1 (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2698377A1 (en) * 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
CN107988428B (zh) * 2017-11-10 2021-04-06 杭州众测生物科技有限公司 虾虹彩病毒(siv)的raa恒温荧光检测方法及试剂
JP2019153618A (ja) * 2018-02-28 2019-09-12 株式会社ジャパンディスプレイ 光センサ装置

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
JPS604422B2 (ja) 1976-10-07 1985-02-04 持田製薬株式会社 抗原の定量方法
IL51667A (en) 1977-03-16 1979-10-31 Miles Yeda Ltd Immunoassay for the determination of a hapten
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4401764A (en) 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
GB2084317B (en) 1980-09-30 1984-01-18 Erba Farmitalia Antigen-linked competitive enzymeimmunoassay
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4661444A (en) 1984-03-29 1987-04-28 Ortho Diagnostic Systems Inc. Homogeneous immunoassays employing double antibody conjugates comprising anti-idiotype antibody
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4746631A (en) 1985-05-09 1988-05-24 Ultra Diagnostics Corporation Immunoassay method, device, and test kit
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
JPH02502251A (ja) 1987-11-13 1990-07-26 ヘルマン　カーティンガー ヒトのモノクローン性抗ｈｉｖ‐１‐抗体
US5244797B1 (en) 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU6523590A (en) 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69130741T2 (de) * 1990-05-16 1999-07-29 Dana-Farber Cancer Institute, Boston, Mass. Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung
ES2089057T3 (es) 1990-07-18 1996-10-01 Abbott Lab Un reactivo sustituto de un analito para uso en metodos de ensayo de fijacion especifica, dispositivos y kits.
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
DE69332744T2 (de) 1992-09-30 2004-01-15 Scripps Research Inst Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5563036A (en) 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
WO1995032307A1 (en) 1994-05-20 1995-11-30 Tularik, Inc. Epstein-barr virus transcription factor binding assay
US5747352A (en) 1994-05-23 1998-05-05 Beckman Instruments, Inc. Reagents and methods for the rapid and quantitative assay of pharmacological agents
US5691147A (en) 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US5627080A (en) 1994-07-29 1997-05-06 Beckman Instruments, Inc. Detergent-facilitated immunoassay for the rapid and quantitative assay of pharmacological agents
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
AU2308595A (en) 1995-04-19 1996-11-07 Polymun Scientific Immunobiologische Forschung Gmbh Monoclonal antibodies against hiv-1 and vaccines made thereo f
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5759781A (en) 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
EP1005481B1 (en) 1997-04-22 2009-10-14 Life Technologies Corporation Methods for the production of aslv reverse transcriptases composed of multiple subunits
US6924112B1 (en) 1997-12-04 2005-08-02 Biomethodes S.A.R.L. Cloning method by multiple-digestion, vectors for implementing same and applications
US6762031B2 (en) * 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
AU2001284999B2 (en) * 2000-08-14 2006-09-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modifications of HIV Env, Gag and Pol enhance immunogenicity for genetic immunization
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
CN102010463A (zh) * 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原
WO2009117661A2 (en) 2008-03-20 2009-09-24 United States Department Of The Army, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Carrier neutralization assay
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
AU2011223677A1 (en) * 2010-03-02 2012-08-30 International Aids Vaccine Initiative Novel HIV-1 envelope glycoprotein
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display

Also Published As

Publication number Publication date
MX348459B (es) 2017-06-14
HUE035432T2 (en) 2018-05-02
RS56707B1 (sr) 2018-03-30
DK2678351T3 (en) 2017-12-04
LT2678351T (lt) 2018-01-25
CN103459410B (zh) 2016-05-25
JP2015508279A (ja) 2015-03-19
WO2012113921A1 (en) 2012-08-30
CA2827967A1 (en) 2012-08-30
SMT201700571T1 (it) 2018-01-11
KR20140025356A (ko) 2014-03-04
CY1119638T1 (el) 2018-04-04
NZ614753A (en) 2015-10-30
ES2651124T3 (es) 2018-01-24
RU2603732C2 (ru) 2016-11-27
AU2012219418C1 (en) 2017-10-05
IL228094A0 (en) 2013-09-30
EP2678351B1 (en) 2017-09-13
JP6140614B2 (ja) 2017-05-31
CN103459410A (zh) 2013-12-18
PL2678351T3 (pl) 2018-03-30
RU2013143295A (ru) 2015-03-27
AU2012219418B2 (en) 2017-05-25
US9605030B2 (en) 2017-03-28
MX2013009757A (es) 2013-12-02
HRP20171697T1 (hr) 2018-01-26
PT2678351T (pt) 2017-12-11
EP2492279A1 (en) 2012-08-29
EP2678351A1 (en) 2014-01-01
US20140037667A1 (en) 2014-02-06
AU2012219418A1 (en) 2013-09-19
ME03045B (me) 2018-10-20

Similar Documents

Publication Publication Date Title
USRE50268E1 (en) Broadly neutralizing antibody and uses thereof
Excler et al. Prospects for a globally effective HIV-1 vaccine
Nachbagauer et al. Universal influenza virus vaccines and therapeutic antibodies
Crooks et al. Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site
Bill Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?
Draper et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
SI2678351T1 (sl) Hiv-gp-120-varianta
JP2011250797A5 (sl)
EP2926830A3 (en) Human immunodeficiency virus (HIV)-neutralizing antibodies
Combadière et al. Peptide-based vaccination for antibody responses against HIV
Kang et al. Immunization with a self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection
Aebischer et al. Development of a modular vaccine platform for multimeric antigen display using an orthobunyavirus model
Chen et al. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
Morales-Hernández et al. Self-assembling protein nanoparticles in the design of vaccines: 2022 update
Klessing et al. CD4+ T cells induced by tuberculosis subunit vaccine H1 can improve the HIV-1 env humoral response by intrastructural help
Gonelli et al. Immunogenicity of HIV-1-based virus-like particles with increased incorporation and stability of membrane-bound Env
WO2011082422A3 (en) Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
WO2009074861A3 (en) Improved vaccine
Hessell et al. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides
Calado et al. A prime-boost immunization strategy with vaccinia virus expressing novel gp120 envelope glycoprotein from a CRF02_AG isolate elicits cross-clade tier 2 HIV-1 neutralizing antibodies
WO2013037841A3 (fr) Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1
Lobaina et al. The nucleocapsid protein of SARS-CoV-2, combined with ODN-39M, is a potential component for an intranasal bivalent vaccine with broader functionality
Luo et al. Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination
Taherkhani et al. A new strategy for development of hepatitis E vaccine: epitope-based vaccines
WO2007137591A8 (en) Hiv vaccine